Patrick Nina M, Griggs Chanel A, Icenogle Ali L, Gilpatrick Maryam M, Kadiyala Vineela, Jaime-Frias Rosa, Smith Catharine L
Department of Pharmaceutical Sciences, College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States; Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States.
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States.
J Steroid Biochem Mol Biol. 2017 Mar;167:1-13. doi: 10.1016/j.jsbmb.2016.09.014. Epub 2016 Sep 16.
Small molecule inhibitors of lysine deacetylases (KDACs) are approved for clinical use in treatment of several diseases. Nuclear receptors, such as the glucocorticoid receptor (GR) use lysine acetyltransferases (KATs or HATs) and KDACs to regulate transcription through acetylation and deacetylation of protein targets such as histones. Previously we have shown that KDAC1 activity facilitates GR-activated transcription at about half of all cellular target genes. In the current study we examine the role of Class I KDACs in glucocorticoid-mediated repression of gene expression. Inhibition of KDACs through two structurally distinct Class I-selective inhibitors prevented dexamethasone (Dex)-mediated transcriptional repression in a gene-selective fashion. In addition, KDAC activity is also necessary to maintain repression. Steroid receptor coactivator 2 (SRC2), which is known to play a vital role in GR-mediated repression of pro-inflammatory genes, was found to be dispensable for repression of glucocorticoid target genes sensitive to KDAC inhibition. At the promoters of these genes, KDAC inhibition did not result in altered nucleosome occupancy or histone H3 acetylation. Surprisingly, KDAC inhibition rapidly induced a significant decrease in H3K4Me2 at promoter nucleosomes with no corresponding change in H3K4Me3, suggesting the activation of the lysine demethylase, LSD1/KDM1A. Depletion of LSD1 expression via siRNA restored Dex-mediated repression in the presence of KDAC inhibitors, suggesting that LSD1 activation at these gene promoters is incompatible with transcriptional repression. Treatment with KDAC inhibitors does not alter cellular levels of LSD1 or its association with Dex-repressed gene promoters. Therefore, we conclude that Class I KDACs facilitate Dex-induced transcriptional repression by suppressing LSD1 complex activity at selected target gene promoters. Rather than facilitating repression of transcription, LSD1 opposes it in these gene contexts.
赖氨酸脱乙酰酶(KDACs)的小分子抑制剂已被批准用于多种疾病的临床治疗。核受体,如糖皮质激素受体(GR),利用赖氨酸乙酰转移酶(KATs或HATs)和KDACs通过对组蛋白等蛋白质靶点进行乙酰化和去乙酰化来调节转录。此前我们已经表明,KDAC1的活性在大约一半的细胞靶基因上促进GR激活的转录。在当前的研究中,我们研究了I类KDACs在糖皮质激素介导的基因表达抑制中的作用。通过两种结构不同的I类选择性抑制剂抑制KDACs,以基因选择性的方式阻止了地塞米松(Dex)介导的转录抑制。此外,KDAC活性对于维持抑制也是必需的。类固醇受体共激活因子2(SRC2),已知在GR介导的促炎基因抑制中起重要作用,但发现其对于对KDAC抑制敏感的糖皮质激素靶基因的抑制是可有可无的。在这些基因的启动子处,KDAC抑制并未导致核小体占有率或组蛋白H3乙酰化的改变。令人惊讶的是,KDAC抑制迅速导致启动子核小体上的H3K4Me2显著减少,而H3K4Me3没有相应变化,这表明赖氨酸去甲基化酶LSD1/KDM1A被激活。通过siRNA耗尽LSD1的表达可在存在KDAC抑制剂的情况下恢复Dex介导的抑制,这表明在这些基因启动子处LSD1的激活与转录抑制不相容。用KDAC抑制剂处理不会改变细胞中LSD1的水平或其与Dex抑制的基因启动子的结合。因此,我们得出结论,I类KDACs通过在选定的靶基因启动子处抑制LSD1复合物的活性来促进Dex诱导的转录抑制。在这些基因环境中,LSD1不是促进转录抑制,而是与之相反。